|Articles|September 11, 2020

AJMC® in the Press, September 11, 2020

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An opinion piece published by The Mercury cited an article published on AJMC.com, the website of The American Journal of Managed Care^®. The article, titled “A Timeline of COVID-19 Developments in 2020,” took a look at how the coronavirus disease 2019 pandemic evolved and progressed from January to June 2020.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

AJMC® in the Press, September 11, 2020

Related Content

$20 Billion National Strategy Aims to Close the Women's Health Gap

Earlier Cancer Screening Could Ease Medicaid Costs: Anuraag R. Kansal, PhD

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Global HepB3 Coverage Reaches 81.8%, but Regional Gaps Persist

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

AJMC® in the Press, September 11, 2020

Related Content

$20 Billion National Strategy Aims to Close the Women's Health Gap

Earlier Cancer Screening Could Ease Medicaid Costs: Anuraag R. Kansal, PhD

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Global HepB3 Coverage Reaches 81.8%, but Regional Gaps Persist

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial